IOVS European Journal of Biochemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yasukawa, T.
Right arrow Articles by Ogura, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yasukawa, T.
Right arrow Articles by Ogura, Y.
(Investigative Ophthalmology and Visual Science. 1999;40:2690-2696.)
© 1999 by The Association for Research in Vision and Ophthalmology, Inc.

Targeted Delivery of Anti–Angiogenic Agent TNP-470 Using Water-Soluble Polymer in the Treatment of Choroidal Neovascularization

Tsutomu Yasukawa1, Hideya Kimura1, Yasuhiko Tabata2, Hideki Miyamoto1, Yoshihito Honda1, Yoshito Ikada2 and Yuichiro Ogura3

1 From the Department of Ophthalmology and Visual Sciences, Graduate School of Medicine and 2 Institute for Frontier Medical Sciences, Kyoto University, Kyoto; and the 3 Nagoya City University Medical School, Aichi, Japan.

PURPOSE. The conjugation of drugs with water-soluble polymers such as poly(vinyl alcohol) (PVA) tends to prolong the half-life of drugs and facilitate the accumulation of drugs in tissues involving neovascularization. The purpose of this study was to evaluate the effect of TNP-470–PVA conjugate on the proliferation of endothelial cells in vitro and on experimental choroidal neovascularization (CNV) in vivo.

METHODS. TNP-470 was conjugated in PVA by a dimethylaminopyridine-catalyzed reaction. The effects of TNP-470–PVA and free TNP-470 on the proliferation of human umbilical vein endothelial cells (HUVECs) and bovine retinal pigment epithelial cells (BRPECs) were evaluated by the tetrazolium-based colorimetric assay (XTT assay). Experimental CNV was induced by subretinal injection of gelatin microspheres containing basic fibroblast growth factor, into rabbits. Thirty rabbits were intravenously treated either with TNP-470–PVA (n = 8), free TNP-470 (n = 5), free PVA (n = 5), or saline (n = 12) daily for 3 days, 2 weeks after implantation of gelatin microspheres. Fluorescein angiography was performed to detect the area with CNV, and the evaluation was made by computerized measurement of digital images. These eyes were also examined histologically. To observe the accumulation of conjugate, 3 rabbits with CNV received rhodamine B isothiocyanate–binding PVA (RITC–PVA), and the lesion was studied 24 hours later by fluorescein microscopy.

RESULTS. The TNP-470–PVA inhibited the growth of HUVECs, similar to that of free TNP-470. The BRPECs were less sensitive to TNP-470–PVA than were the HUVECs. TNP-470–PVA significantly inhibited the progression of CNV in rabbits (P = 0.001). Histologic studies at 4 weeks after treatment demonstrated that the degree of vascular formation and the number of vascular endothelial cells in the subretinal membrane of the eyes treated with TNP-470–PVA were less than those of the control eyes. RITC–PVA remained in the area with CNV 24 hours after administration.

CONCLUSIONS. These results suggest that TNP-470–PVA inhibited the proliferation of HUVECs more sensitively than that of BRPECs, and the targeted delivery of TNP-470–PVA may have potential as a treatment modality for CNV.




This article has been cited by other articles:


Home page
IOVSHome page
Y. Yanagi, Y. Tamaki, Y. Inoue, R. Obata, K. Muranaka, and N. Homma
Subconjunctival Doxifluridine Administration Suppresses Rat Choroidal Neovascularization through Activated Thymidine Phosphorylase
Invest. Ophthalmol. Vis. Sci., February 1, 2003; 44(2): 751 - 754.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
S. Einmahl, M. Savoldelli, F. D'Hermies, C. Tabatabay, R. Gurny, and F. Behar-Cohen
Evaluation of a Novel Biomaterial in the Suprachoroidal Space of the Rabbit Eye
Invest. Ophthalmol. Vis. Sci., May 1, 2002; 43(5): 1533 - 1539.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
T. Yasukawa, H. Kimura, Y. Tabata, H. Kamizuru, H. Miyamoto, Y. Honda, and Y. Ogura
Targeting of Interferon to Choroidal Neovascularization by Use of Dextran and Metal Coordination
Invest. Ophthalmol. Vis. Sci., March 1, 2002; 43(3): 842 - 848.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
A. M. Joussen, W.-D. Beecken, Y. Moromizato, A. Schwartz, B. Kirchhof, and V. Poulaki
Inhibition of Inflammatory Corneal Angiogenesis by TNP-470
Invest. Ophthalmol. Vis. Sci., October 1, 2001; 42(11): 2510 - 2516.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
H. Kamizuru, H. Kimura, T. Yasukawa, Y. Tabata, Y. Honda, and Y. Ogura
Monoclonal Antibody-Mediated Drug Targeting to Choroidal Neovascularization in the Rat
Invest. Ophthalmol. Vis. Sci., October 1, 2001; 42(11): 2664 - 2672.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the Association for Research in Vision and Ophthalmology